Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
04 November 2019 - 10:30PM
Biogen to Host Investor Webcasts from Clinical Trials on
Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Biogen (Nasdaq: BIIB) today announced it will host live webcasts of
its oral presentation and a Q&A session related to its
Alzheimer’s disease investigational therapy, aducanumab, at the
upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual
congress in San Diego, California.
Webcast Details:
- Thursday, December 5, 2019, 11:00 a.m. ET / 8:00 a.m. PT –
Aducanumab Phase 3 topline results
- Thursday, December 5, 2019, 5:00 p.m. ET / 2:00 p.m. PT –
Investor Q&A call with Alfred Sandrock, Jr., M.D., Ph.D.,
Executive Vice President R&D and Chief Medical Officer at
Biogen, and Samantha Budd Haeberlein, Ph.D., Vice President,
Alzheimer’s Disease, Dementia and Movement Disorders, Late Stage
Clinical Development at Biogen
To access the live webcasts, please go to the Investors section
of Biogen’s website at investors.biogen.com. Following the
live webcasts, archived versions will be available on the
website.
About Biogen At Biogen, our mission is clear:
we are pioneers in neuroscience. Biogen discovers, develops, and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics, and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, neuromuscular disorders, movement disorders,
Alzheimer’s disease and dementia, ophthalmology, immunology,
neurocognitive disorders, acute neurology, and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
About AducanumabAducanumab (BIIB037) is an
investigational human monoclonal antibody studied for the treatment
of early Alzheimer’s disease. Biogen licensed aducanumab from
Neurimmune under a collaborative development and license agreement.
Since October 2017, Biogen and Eisai have collaborated on the
development and commercialization of aducanumab globally.
EMERGE and ENGAGE were Phase 3 multicenter, randomized,
double-blind, placebo-controlled, parallel-group studies designed
to evaluate the efficacy and safety of aducanumab. The primary
objective of the studies was to evaluate the efficacy of monthly
doses of aducanumab as compared with placebo in reducing cognitive
and functional impairment as measured by changes in the Clinical
Dementia Rating-Sum of Boxes (CDR-SB) score. Secondary objectives
were to assess the effect of monthly doses of aducanumab as
compared to placebo on clinical decline as measured by the
Mini-Mental State Examination (MMSE), the Alzheimer’s Disease
Assessment Scale-Cognitive Subscale 13 Items (ADAS-Cog 13), and the
Alzheimer’s Disease Cooperative Study-Activities of Daily Living
Inventory Mild Cognitive Impairment Version (ADCS-ADL-MCI).
|
|
MEDIA CONTACT: David Caouette
+1 617 679 4945public.affairs@biogen.com |
INVESTOR CONTACT: Joe Mara+1 781
464 2442 IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biogen (TG:IDP)
Historical Stock Chart
Von Apr 2023 bis Apr 2024